Bridging the Age Gap in breast cancer: Impact of chemotherapy on quality of life in older women with early breast cancer

Abstract

Introduction Older patients with early breast cancer (EBC) derive modest survival benefit from chemotherapy but have increased toxicity risk. Data on the impact of chemotherapy for EBC on quality of life in older patients are limited, but this is a key determinant of treatment acceptance. We aimed to investigate its effect on quality of life in older patients enrolled in the Bridging the Age Gap study. Materials and methods A prospective, multicentre, observational study of EBC patients ≥70 years old was conducted in 2013–2018 at 56 UK hospitals. Demographics, patient, tumour characteristics, treatments and adverse events were recorded. Quality of life was assessed using the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaires (EORTC-QLQ) C30, BR23 and ELD 15 plus the Euroqol-5D (eq-5d) over 24 months and analysed at each time point using baseline adjusted linear regression analysis and propensity score-matching. Results Three thousand and four hundred sixteen patients were enrolled in the study; 1520 patients undergoing surgery and who had high-risk EBC were included in this analysis. 376/1520 (24.7%) received chemotherapy. At 6 months, chemotherapy had a significant negative impact in several EORTC-QLQ-C30 domains, including global health score, physical, role, social functioning, cognition, fatigue, nausea/vomiting, dyspnoea, appetite loss, diarrhoea and constipation. Similar trends were documented on other scales (EORTC-QLQ-BR23, EORTC-QLQ-ELD15 and EQ-5D-5L). Its impact was no longer significant at 18–24 months in unmatched and matched cohorts. Conclusions The negative impact of chemotherapy on quality-of-life is clinically and statistically significant at 6 months but resolves by 18 months, which is crucial to inform decision-making for older patients contemplating chemotherapy. Trial registration number ISRCTN 46099296.

Is adjuvant chemotherapy necessary in older patients with breast cancer?

“…Among 127 patients receiving chemotherapy, results showed that 46 (36.2%) patients experienced adverse events and 54 (42.5%) reduced or discontinued chemotherapy. There was no chemotherapy-related death reported, similar to previous studies [11,12]. Our results showed that adjuvant chemotherapy did not improve OS in the matching cohort (Fig.…”

Personalising therapy for early-stage oestrogen receptor-positive breast cancer in older women

“…After active treatment, there might be long-term sequelae, with which patients must then contend, including physical, functional, and psychosocial effects that can lead to patients requiring help with basic or instrumental daily activities. Although the impact of chemotherapy on quality of life could be transient, 94 these implications might be less acceptable for older patients with fewer years of life remaining than for younger patients. It is the task of the medical oncologist and care team to minimise and prevent cancer morbidity and to ensure that cancer therapies help more than they harm.…”

Value in oncology from multi-criteria decision analysis: A systematic review

“…Several particularities support this relevance in this population, such as the significant increase in therapeutic alternatives (e.g., the increasing use of monoclonal antibodies for different cancers) and the need to evaluate the particular risk-benefit profile according to numerous clinical stages and molecular typification (e.g., different prognosis and chemotherapy protocols in case of presence of HER-2 in breast cancer) (9,10). Other factors include the high impact of the adverse effects on the patient's quality of life and the need for treatment by multidisciplinary teams (e.g., surgeons, clinical oncologists, palliative care) (9)(10)(11)(12)(13). These unique attributes might explain the high cost for the health system and the patients affected by this condition (14,15).…”